BioAffinity Technologies’ CyPath lung cancer test supported in publication

bioAffinity Technologies’ Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the peer-reviewed paper, “Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain,” in the journal Cytometry Part B: Clinical Cytometry, the official journal of the International Clinical Cytometry Society. “Our CyPath Lung noninvasive test for the early detection of lung cancer is a novel test that uses sputum, a unique sample type that is not typically used in clinical flow cytometry assays,” Rebeles said. Flow cytometry is a well-established technology used in both research and clinical practice because of its ability to rapidly measure physical and chemical properties of cells in biological samples. The paper supplements the Clinical and Laboratory Standards Institute CLSI Guideline H62, the standard for validating assays performed by flow cytometry issued in 2021, by addressing challenges and considerations in validation with unique sample types…”It is gratifying to see our workgroup’s recommendations shared with the clinical cytometry community. The panel’s work acknowledges and encourages the validation of rare matrices in flow cytometry for clinical use,” Rebeles said.